ArticleSmall (Weinheim an der Bergstrasse, Germany)2016
Facile Fabrication of Tumor Redox-Sensitive Nanoassemblies of Small-Molecule Oleate Prodrug as Potent Chemotherapeutic Nanomedicine.
Article in Small (Weinheim an der Bergstrasse, Germany), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 172 citations in OpenAlex.
- Glucose-functionalized redox-responsive dihydroartemisinin prodrug nanosystem for targeted malaria therapy.International journal of pharmaceutics: X · 2025Article
- Application of photodynamic activation of prodrugs combined with phototherapy in tumor treatment.Molecular cancer · 2025Review
- A comprehensive review on the latest advances of dimeric anticancer prodrugs.Future medicinal chemistry · 2025Review
- A minimalist multifunctional nano-prodrug for drug resistance reverse and integration with PD-L1 mAb for enhanced immunotherapy of hepatocellular carcinoma.Journal of nanobiotechnology · 2024Article
- A natural compound-empowered podophyllotoxin prodrug nanoassembly magnifies efficacy-toxicity benefits in cancer chemotherapy.Asian journal of pharmaceutical sciences · 2024Article
- Self-assembled nanoformulations of paclitaxel for enhanced cancer theranostics.Acta pharmaceutica Sinica. B · 2023Review
- Redox-Responsive Lipidic Prodrug Nano-Delivery System Improves Antitumor Effect of Curcumin Derivative C210.Pharmaceutics · 2023Article
- Selective ischemic-hemisphere targeting Ginkgolide B liposomes with improved solubility and therapeutic efficacy for cerebral ischemia-reperfusion injury.Asian journal of pharmaceutical sciences · 2023Article
- Reduction-Responsive Stearyl Alcohol-Cabazitaxel Prodrug Nanoassemblies for Cancer Chemotherapy.Pharmaceutics · 2023Article
- Disulfide Bond-Based SN38 Prodrug Nanoassemblies with High Drug Loading and Reduction-Triggered Drug Release for Pancreatic Cancer Therapy.International journal of nanomedicine · 2023Article
- Oxidative stress induced by berberine-based mitochondria-targeted low temperature photothermal therapy.Frontiers in chemistry · 2023Article
- Improving cellular uptake and bioavailability of periplocymarin-linoleic acid prodrug by combining PEGylated liposome.Drug delivery · 2022Article
- Smart drug delivery systems for precise cancer therapy.Acta pharmaceutica Sinica. B · 2022Review
- Elaborately engineering of a dual-drug co-assembled nanomedicine for boosting immunogenic cell death and enhancing triple negative breast cancer treatment.Asian journal of pharmaceutical sciences · 2022Article
- Elaborately Engineering a Self-Indicating Dual-Drug Nanoassembly for Site-Specific Photothermal-Potentiated Thrombus Penetration and Thrombolysis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Article
- Engineering of small-molecule lipidic prodrugs as novel nanomedicines for enhanced drug delivery.Journal of nanobiotechnology · 2022Review
- Light-activated nanomaterials for tumor immunotherapy.Frontiers in chemistry · 2022Review
- Two-Pronged Anti-Tumor Therapy by a New Polymer-Paclitaxel Conjugate Micelle with an Anti-Multidrug Resistance Effect.International journal of nanomedicine · 2022Article
- A redox-responsive dihydroartemisinin dimeric nanoprodrug for enhanced antitumor activity.Journal of nanobiotechnology · 2021Article
- Effect of XlogP and hansen solubility parameters on the prediction of small molecule modified docetaxel, doxorubicin and irinotecan conjugates forming stable nanoparticles.Drug delivery · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
Abstract
The conjugate of paclitaxel (PTX) and docosahexaenoic acid has entered into clinical trials. However, the most recent clinical outcomes fell short of expectations, due to the extremely slow drug release from the hydrophobic conjugates. Herein, a novel prodrug-based nanoplatform self-assembled by the disulfide bond linked conjugates of PTX and oleic acid for rapid and differential release of PTX in tumor cells is reported. This redox-responsive prodrug-nanosystem demonstrates multiple therapeutic advantages, including one-step facile fabrication, high drug-loading efficiency (56%, w/w), on-demand drug release responding to redox stimuli, as well as favorable cellular uptake and biodistribution. These advantages result in significantly enhanced antitumor efficacy in vivo, with the tumor almost completely disappearing in mice. Such a uniquely engineered prodrug-nanosystem has great potential to be used as potent chemotherapeutic nanomedicine in clinical cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.